Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners

Acquisition Overview - GHO Capital Partners and Ampersand Capital Partners have successfully closed the acquisition of Avid Bioservices, a dedicated biologics Contract Development and Manufacturing Organisation (CDMO), in an all-cash transaction valued at approximately $1.1 billion [1][4][7] - Avid's stockholders will receive$12.50 per share in cash, and the company's common stock will be delisted from Nasdaq [4][7] Company Growth and Capabilities - Avid has experienced significant growth, offering full lifecycle capabilities from concept to commercial supply, with substantial investments in state-of-the-art facilities and expertise in bioprocess optimization, analytical testing, and regulatory compliance [2][9] - The company provides a comprehensive range of services including CGMP clinical and commercial drug substance manufacturing, bulk packaging, and regulatory submissions support, leveraging over 30 years of experience in producing biologics [9] Strategic Focus of GHO and Ampersand - GHO has considerable expertise in the CDMO sector, focusing on expanding technological capabilities, driving acquisitions, and supporting transatlantic expansion across the CDMO value chain [3][10] - Ampersand Capital Partners, with $3 billion in assets under management, is dedicated to growth-oriented investments in the healthcare sector, leveraging a blend of private equity and operating experience to build value [10] Leadership Insights - GHO's Managing Partners expressed excitement about the acquisition, highlighting Avid's strong foundation for future growth and the potential to unlock the business's full potential [4] - Avid's President and CEO noted that the new ownership will provide access to resources that will accelerate growth and enhance capabilities [4]